About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« More From the Me-Too Front | Main | Things I Won't Touch (1) »

March 2, 2004

Catching Up

Email This Entry

Posted by Hylton Jolliffe

Little time for blogging the last day or two. I've been finishing up a paper to send to Bioorganic and Medicinal Chemistry Letters, the first one I've written in a while, and I'm checking over another paper that I'm a coauthor on. We're deciding on where to send that one - the lead author suggested Tetrahedron Letters as a possibility, and I thought "Hmm. I haven't had a paper in Tet. Lett. for quite a while." Which was true - a moment later, I realized that the last time was twenty years ago this year! I'm just glad that I usually don't feel as old as that makes me sound. (Talk to me twenty years from now.)

Matthew Holt has a long article on his site that's well worth reading. I'm going to write in response to it this week, because I think a few of its assumptions are incorrect, but it's a good piece nonetheless. It's yet another in the saga of drug prices and research costs, whichs bids fair to be an inexhaustible topic. I am not, though, an inexhaustible blogger. After this round, I'm going to take some time off the topic to recharge my argumentative batteries.

I have a number of other topics backed up in my queue. And I'm going to start off a new occasional feature, a complement to my "How Not to Do It" series of lab stories. This one will be "Things I Won't Touch", and will feature a different reagent each time that I refuse to ever work with. It's a fairly lengthy list, and I'm only a moderately cautious guy. (If anyone else out there has made fluorosulfonic acid from scratch, starting with concentrated hydrofluoric acid and KOH pellets, I'd be glad to hear from you. We can start a club. Admittedly, I was young and foolish at the time, but I made it through without destroying any property. Mostly.)

And one more thing tonight: I'd like to thank everyone for making February by far my highest-traffic month ever. There were about 25,000 page views, which is a roundoff error for the likes of Glenn Reynolds, but thoroughly broke my old record. Much of that was due to my broadside against Gregg Easterbrook, which he certainly seemed to recover from nicely.

Comments (0) + TrackBacks (0) | Category: Blog Housekeeping | The Scientific Literature



Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry